Enzymotec Ltd. provided earnings guidance for the fourth quarter and full year ended December 31, 2016. For the quarter, the company expects to report net revenues of $10.6 million. Net revenues (utilizing the proportionate consolidation method that is used for segment reporting) are expected to amount to $13.5 million for the fourth quarter of 2016. The company expects to report a non-GAAP loss per share of $0.10 in the fourth quarter, compared to its previously announced guidance of non-GAAP earnings per share of $0.02 to $0.04. Non-GAAP earnings per share was primarily impacted by an inventory write-off of $2.0 million, or $0.09 per share, and to a lesser extent by, $0.35 million, or $0.02 per share, due to the depreciation of the euro relative to the U.S. dollar during the fourth quarter of 2016. Preliminary GAAP diluted loss per share expected to be $0.18. For the full year, the company expects to report net revenues of $47.7 million. Net revenues (utilizing the proportionate consolidation method that is used for segment reporting) are expected to amount to $60.9 million for the full year ended December 31, 2016.